Treating Clozapine-induced Sinustachycardia With Bisoprolol (Biscloz)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00882856
Recruitment Status : Completed
First Posted : April 17, 2009
Last Update Posted : January 9, 2017
Aalborg Universitetshospital
Aalborg University
Information provided by (Responsible Party):
University of Aarhus

Brief Summary:
Clozapine-induced sinustachycardia occurs in 25% of patients treated with clozapine and sustained sinustachycardia might be a risk factor for dilated cardiomyopathy. This double-blinded cross over placebo controlled study investigate whether 10 mg bisoprolol are efficient in treating clozapine-induced sinustachycardia measured as heart rate, heart rate variability, QTc and T-wave morphology.

Condition or disease Intervention/treatment Phase
Clozapine-induced Sinustachycardia Drug: Bisoprolol Drug: Placebo Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Treating Clozapine-induced Sinustachycardia With Bisoprolol - a Double Blinded Placebo Controlled Cross Over Study
Study Start Date : April 2009
Actual Primary Completion Date : December 2016
Actual Study Completion Date : December 2016

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Bisoprolol-washout -placebo
Bisoprolol - wash out - placebo
Drug: Bisoprolol
Bisoprolol "Vitabalnas" 10 mg once daily
Other Name: Bisoprolol "Vitabalans"

Drug: Placebo

Active Comparator: Placebo - wash out - bisoprolol
Placebo - wash out - bisoprolol
Drug: Bisoprolol
Bisoprolol "Vitabalnas" 10 mg once daily
Other Name: Bisoprolol "Vitabalans"

Drug: Placebo

Primary Outcome Measures :
  1. Heart rate variability [ Time Frame: Baseline, visit 1+2+3 ]

Secondary Outcome Measures :
  1. QTc, T-wave morphology and other ECG markers [ Time Frame: Baseline, visit 1+2+3 ]
  2. Hamilton-Anxiety scale [ Time Frame: Baseline, visit 1+2+3 ]
  3. Salivation rate [ Time Frame: Baseline, visit 1+2+3 ]
  4. Orthostatic blood pressure [ Time Frame: Baseline, visit 1+2+3 ]
  5. WHO-QoL [ Time Frame: Baseline, visit 1+2+3 ]
  6. Nocturnal Hypersalivation Rating Scale (NHRS). [ Time Frame: Baseline, visit 1+2+3 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Treated with clozapine > 3 months and minimum 100 mg/day
  • Fixed dose 14 days before inclusion
  • Heart rate > 100 (ECG)
  • Pregnancy test negative
  • Clozapine-induced sinustachycardia documented by ECG or case record
  • Sexual abstinence or contraception
  • Informed consent

Exclusion Criteria:

  • Substance abuse
  • Physical diseases, contraindications for clozapine or bisoprolol
  • Asthma or chronic obstructive lung disease
  • Blood pressure < 100/60 or recent history of syncopes
  • QTc>500 ms, SA-block, AV- block II or III
  • Restrictions by Danish mental act
  • Allergic to clozapine or bisoprolol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00882856

Aalborg University Hospital, Psychiatry
Aalborg, Denmark, 9000
Sponsors and Collaborators
University of Aarhus
Aalborg Universitetshospital
Aalborg University
Study Director: Ole Schjerning, M.D. Aalborg Universitetshospital

Responsible Party: University of Aarhus Identifier: NCT00882856     History of Changes
Other Study ID Numbers: 2009-09215-22/5.1. 22AUG2011
First Posted: April 17, 2009    Key Record Dates
Last Update Posted: January 9, 2017
Last Verified: January 2017

Keywords provided by University of Aarhus:
Heartrate variability

Additional relevant MeSH terms:
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
GABA Antagonists
GABA Agents
Antihypertensive Agents
Autonomic Agents
Peripheral Nervous System Agents
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents